StemCells Inc  

(Public, NASDAQ:STEM)   Watch this stock  
Find more results for STEM
0.679
May 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 0.54 - 2.43
Open     -
Vol / Avg. 0.00/2.44M
Mkt cap 71.33M
P/E     -
Div/yield     -
EPS -0.52
Shares 104.44M
Beta 1.54
Inst. own 10%
Aug 10, 2015
Q2 2015 StemCells Inc Earnings Release (Estimated) Add to calendar
May 28, 2015
StemCells Inc at Marcum MicroCap Conference - 1:30PM EDT - Add to calendar
May 5, 2015
Q1 2015 StemCells Inc Earnings Call - Webcast
May 5, 2015
Q1 2015 StemCells Inc Earnings Release
Apr 27, 2015
GTC Stem Cell Summit 2015
Apr 15, 2015
StemCells Inc at Needham Healthcare Conference
Mar 16, 2015
Q4 2014 StemCells Inc Earnings Call - Webcast
Mar 16, 2015
Q4 2014 StemCells Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -44527.14% -3186.58%
Operating margin -42668.52% -3294.23%
EBITD margin - -2924.08%
Return on average assets -139.75% -87.21%
Return on average equity -2128.21% -309.83%
Employees 69 -
CDP Score - -

Address

3155 PORTER DRIVE
PALO ALTO, CA 94304
United States - Map
+1-650-4753100 (Phone)
+1-510-4564001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

StemCells, Inc. (StemCells) is engaged in the research, development, and commercialization of stem cell therapeutics and related tools and technologies for academia and industry. The Company is focused on developing and commercializing stem and progenitor cells as the basis for therapeutics and therapies, and cells and related tools and technologies to enable stem cell-based research and drug discovery and development. The Company’s primary research and development efforts are focused on identifying and developing stem and progenitor cells as potential therapeutic agents. The Company’s lead product development programs include its CNS Program, which is developing applications for HuCNS-SC cells, its human neural stem cell product candidate.

Officers and directors

John J. Schwartz Ph.D. Independent Chairman of the Board
Age: 80
Bio & Compensation  - Reuters
Ian J. Massey Ph.D. President, Chief Operating Officer
Age: 65
Bio & Compensation  - Reuters
Martin M. McGlynn Chief Executive Officer, Director
Age: 69
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Gregory T. Schiffman Chief Financial Officer, Executive Vice President - Finance
Age: 57
Bio & Compensation  - Reuters
Ann Tsukamoto Ph.D. Executive Vice President - Scientific and Strategic Alliances
Age: 62
Bio & Compensation  - Reuters
Kenneth Blair Stratton J.D. General Counsel
Age: 46
Bio & Compensation  - Reuters
Alan O. Trounson Ph.D. Director
Age: 69
Bio & Compensation  - Reuters
Irving L. Weissman M.D. Director
Age: 75
Bio & Compensation  - Reuters
Eric H. Bjerkholt Independent Director
Age: 55
Bio & Compensation  - Reuters
R. Scott Greer Independent Director
Age: 56
Bio & Compensation  - Reuters